ClinicalTrials.gg
RecruitingNCT06414655ChiTwiMCUpdated May 16, 2024

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China

An observational study in Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition and Pre-Term, sponsored by Peking University Third Hospital. Recruiting at 11 sites in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Peking University Third Hospital · Observational

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China (ChiTwiMC) is supported by National Key Research and Development Program of China - Reproductive Health and Women's and Children's Health Protection Project. This project is funded by the Ministry of Science and Technology of China under grant number 2023YFC2705900. The ChiTwiMC cohort is led by Professor Wei Yuan from the Department of Gynecology and Obstetrics at Peking University Third Hospital.

Read the detailed description

The ChiTwiMC Cohort focusing on the serious complications of twin pregnancy, establish a multicenter large prospective mother-child cohort of twin pregnancy covering pregnancy→neonatal period→early childhood, and a multi-variety, multi-stage biobank for the study of adverse outcomes of twin pregnancy. The ChiTwiMC Cohort is planning to recruit 2000 pregnant women aged 18-45 years from 9 large obstetrical center of major University-affiliated Hospitals across China, between December 2023 and May 2026. All women will be enrolled prior to 14 wks of gestation, pregnancy was followed up at 22-28 wks, 30-38 wks of gestation, delivery, postpartum 42 days, 6 months, 12 months. Data including demographics, medical history, reproductive history, clinical diagnosis, treatment information, and pregnancy and birth outcomes will be collected via electronic data capture system. Track the outcome of severe maternal-fetal complications and early neonatal outcomes of twins, and collect biological samples, including peripheral venous blood, hair and cervicovaginal secretions from pregnant women, placenta tissue, amniotic fluid and unbilical cord blood at delivery, meconium and hair from newborns, buccal mucosa from infants and peripheral venous blood from the husband.

02

Conditions studied

  • Twin Pregnancy, Antepartum Condition or Complication
  • Twin to Twin Transfusion as Antepartum Condition
  • Pre-Term
  • Pre-Eclampsia
  • Twin Monochorionic Diamniotic Placenta
  • Twin Dichorionic Diamniotic Placenta
  • High Risk Pregnancy
  • Twin Placenta
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 120 across 806 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The ChiTwiMC is a prospective cohort that will enroll 2000 pregnant women aged 18-45 years and over from 9 large obstetrical centers of University-Affiliated Hospitals (Peking University Third Hospital; First Affiliated Hospital, Sun Yat-Sen University; Chongqing Medical University; Shengjing Hospital; Shanghai First Maternity and Infant Hospital; The First Affiliated Hospital of Anhui Medical University; International Peace Maternity and Child Health Hospital; The Second Hospital of Shandong University; Shandong Provincial Hospital). These hospitals located at 7 supercities (Beijing, Shanghai, Guangzhou, Shenyang, Jinan, Chongqing, and Hefei) of China. Pregnant women who are planning to receive prenatal healthcare and delivery in those hospitals are potential candidates for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Twin pregnancies
  • Female aged between 18-45 years
  • Gestational age is less than 14 weeks
  • Planning to receive prenatal healthcare and delivery service at the study hospital
  • Signing informed concent and willing to participate

Exclusion criteria

Exclusion Criteria:

  • Women with mental disorders or serious maternal illness that is not eligible to participate
  • Inability to provide
  • Pregnant women not registered in our hospital
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
None retained
06

What researchers measure

Primary outcomes

  1. Rate of preterm delivery

    Preterm delivery is defined as delivery between 28 and 37 gestational weeks.

    Time frame: From inclusion to delivery

  2. Rate of preeclampsia

    Preeclampsia is defined as the condition occurring in pregnant women after 20 weeks of gestation, characterized by systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, accompanied by any of the following: a urinary protein quantification ≥0.3 g/24 h, or a urine protein/creatinine ratio ≥0.3, or random urine protein ≥ (+) (as a method of examination when protein quantification is not feasible). In the absence of proteinuria, the condition may still be diagnosed if there is involvement of any organ or system, including but not limited to critical organs such as the heart, lungs, liver, kidneys, or abnormalities in the hematological, digestive, or neurological systems, as well as complications affecting the placenta-fetus.

    Time frame: From inclusion to delivery

  3. Rate of twin-to-twin transfusion syndrome (TTTS)

    TTTS is diagnosed in monochorionic diamniotic twin pregnancies when there is a discordance in amniotic fluid volumes, with one fetus exhibiting polyhydramnios and the other oligohydramnios. Specifically, before 20 weeks of gestation, the condition is diagnosed if one fetus (the recipient) has a deepest vertical pocket (DVP) of amniotic fluid ≥8cm, while the other fetus (the donor) has a DVP ≤2cm; after 20 weeks of gestation, the diagnosis is made if one fetus (the recipient) has a DVP ≥10cm, while the other fetus (the donor) has a DVP ≤2cm.

    Time frame: From inclusion to delivery

  4. Rate of selective fetal growth restriction (sFGR)

    sFGR is diagnosed in monochorionic diamniotic twin pregnancies when one fetus has an estimated fetal weight below the 10th percentile for its gestational age, and there is a discrepancy of ≥25% in the estimated fetal weights between the two fetuses.

    Time frame: From inclusion to delivery

  5. Rate of fetal brain injury

    Fetal brain injury is an abnormality in the structural and functional integrity of the cerebrum, cerebellum, or brainstem during the gestational period, caused by various factors such as hypoxic-ischemic events, infections, hemorrhage, congenital malformations, and genetic metabolic disorders.

    Time frame: From inclusion to delivery

  6. Rate of neonatal brain injury

    Brain injury refers to damage to the central nervous system resulting from various risk factors during pregnancy, childbirth, and the neonatal period. Clinically, it manifests as central motor disorders, cognitive impairments, language disorders, visual and auditory impairments, as well as difficulties in social interaction and psychological and behavioral disorders. It needs pregnant history or birth history, (such as one of twin intrauterine fetal death, Intrauterine distress), manifestation, and ultrasound, CT, MRI, electroencephalogram to make a definite diagnosis.

    Time frame: From inclusion to delivery

  7. Rate of early childhood developmental delay of the offspring

    Early childhood developmental delay of the offspring refers to a significant lag or delay in achieving age-appropriate developmental milestones across one or more domains, including cognitive, language, motor, social-emotional, and adaptive skills, during the early years of life (typically from birth to 5 years of age) in comparison to established norms or peers. The assessment of early childhood developmental delay is conducted using standardized scales such as Ages Stages Questionnaires (Third Edition), Gesell Developmental Schedules, and Bayley Scales of Infant and Toddler Development. The actual measurement process will be depending on the routine pediatric settings and resources available at each participating institution.

    Time frame: Within 1 year after delivery

  8. Children's height

    Each child is measured twice. If the difference is less than 0.1 cm, the average of the two measurements is taken. If the difference is greater than 0.1 cm, the measurement is repeated.

    Time frame: Within 1 year after delivery

  9. Children's weight

    Each newborn is measured twice. If the difference is less than 0.01 kg, the average of the two measurements is taken. If the difference is greater than 0.01 kg, the measurement is repeated.

    Time frame: Within 1 year after delivery

Secondary outcomes

  1. Rate of sleep disorders

    Women's physiological and psychological changes during pregnancy will affect sleep, and the occurrence of bad sleep during pregnancy is more common. It is generally assessed by a sleep questionnaire.

    Time frame: From inclusion to delivery

  2. Rate of mental and phycological disorders

    Maternal mental health is as important as physical health, and good maternal mental health helps to promote the physical and mental health of the baby, as well as their own physical condition and natural childbirth. The condition of pregnant women is generally assessed by psychiatric departments.

    Time frame: From inclusion to delivery

  3. Rate of single intrauterine fetal demise

    The death of one fetus for twin pregnancy,the occurrence in the second and third trimesters of pregnancy has substantial adverse effects on surviving infants.

    Time frame: From inclusion to delivery

  4. Rate of gestational hypertension

    Take two consecutive measurements on the same arm, the systolic blood pressure more than 140 mmHg and (or) the diastolic blood pressure more than 90 mmHg. High blood pressure may lead to severe complications such as preclampsia and clampsia.

    Time frame: From inclusion to delivery

  5. Rate of gestational diabetes mellitus

    Diagnosed with gestational diabetes through an oral glucose tolerance test (OGTT). The blood glucose threshold of fasting, 1 h and 2 h after taking oral glucose was 5.1, 10.0, 8.5 mmolL, respectively, and the blood glucose level reached or exceeded the above criteria at any time point was diagnosed as GDM. GDM is clearly associated with adverse pregnancy outcomes such as fetal macrosomia, cesarean section delivery, preterm birth, and preeclampsia

    Time frame: From inclusion to delivery

  6. Number of maternal death

    Deaths during pregnancy or less than 42 days after termination of pregnancy.

    Time frame: From inclusion to delivery

  7. Rate of stillbirth

    After 28 gestational weeks, the fetus dies before or during delivery

    Time frame: From inclusion to delivery

  8. Birth weight

    Each newborn is measured twice. If the difference is less than 0.01 kg, the average of the two measurements is taken. If the difference is greater than 0.01 kg, the measurement is repeated.

    Time frame: At delivery

  9. Birth length

    Each newborn is measured twice. If the difference is less than 0.1 cm, the average of the two measurements is taken. If the difference is greater than 0.1 cm, the measurement is repeated.

    Time frame: At delivery

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — We have decided that the program will be confidential and not open to other researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06414655
Collaborators
First Affiliated Hospital, Sun Yat-Sen University, Chongqing Medical University, Shengjing Hospital, Peking University, Nankai University, Shanghai First Maternity and Infant Hospital, The First Affiliated Hospital of Anhui Medical University, International Peace Maternity and Child Health Hospital, The Second Hospital of Shandong University, Shandong Provincial Hospital
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Mar 1, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 16, 2024

Study contacts

Yuan Wei, PhD, MD
Contact
weiyuanbysy@163.com
01082267852
Tianchen Wu, PhD
Contact
wtc17@pku.edu.cn
Yuan Wei, PhD, MD
study chair · Obstetrics and Gynecology Department of Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion